News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Ark Therapeutics’ Phase III Brain Cancer Drug Trial Cleared To Continue Update
January 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (AFX) - Ark Therapeutics Group PLC's final-stage trial of an experimental drug to treat brain cancer has been cleared to continue without modification, by Europe's medicine safety board.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Regulatory
Europe
MORE ON THIS TOPIC
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
·
1 min read
·
Jennifer Smith-Parker
Government
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
February 19, 2026
·
3 min read
·
Tristan Manalac
Regulatory
It’s Official: FDA Will Now Default to One Clinical Trial for Drug Applications
February 19, 2026
·
3 min read
·
Tristan Manalac
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
·
2 min read
·
Jennifer Smith-Parker
